TuisROIV • NASDAQ
add
Roivant Sciences Ltd
Vorige sluiting
$11,20
Dagwisseling
$11,11 - $11,44
Jaarwisseling
$8,73 - $13,06
Markkapitalisasie
7,63 mjd USD
Gemiddelde volume
5,58 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 7,57 m | -16,08% |
Bedryfskoste | 227,69 m | 128,37% |
Netto inkomste | -206,48 m | -36,63% |
Netto winsgrens | -2,73 k | -62,81% |
Wins per aandeel | -0,22 | 6,85% |
EBITDA | -357,00 m | -95,25% |
Effektiewe belastingkoers | -24,29% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 4,89 mjd | -24,76% |
Totale bates | 5,44 mjd | -24,72% |
Totale aanspreeklikheid | 249,74 m | -67,73% |
Totale ekwiteit | 5,19 mjd | — |
Uitstaande aandele | 679,81 m | — |
Prys om te bespreek | 1,66 | — |
Opbrengs op bates | -16,26% | — |
Opbrengs op kapitaal | -16,71% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -206,48 m | -36,63% |
Kontant van bedrywe | -172,56 m | -59,11% |
Kontant van beleggings | 1,07 mjd | 15 405,11% |
Kontant van finansiering | -177,15 m | -443,01% |
Netto kontantverandering | 723,99 m | 636,25% |
Beskikbare kontantvloei | -15,51 m | 81,83% |
Meer oor
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
HUB
Gestig
07 Apr. 2014
Webwerf
Werknemers
750
